Mark Hensley
Vermögen: 84 767 $ am 31.07.2026
Vermögen: 84 767 $ am 31.07.2026
Mark E.
Hensley is currently Chairman at Calliditas Therapeutics AB and Chief Operating Officer & Executive Vice President at Heron Therapeutics, Inc. starting in 2025.
Formerly, Mr. Hensley was Chief Commercial Officer at Veloxis Pharmaceuticals A from 2018 to 2021.
Education includes an undergraduate degree from the University of North Texas.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
HERON THERAPEUTICS INC 0,09 % | 06.08.2026 | 170.901 ( 0,09 % ) | 84 767 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CALLIDITAS THERAPEUTICS AB | Vorsitzender | - |
| HERON THERAPEUTICS, INC. | Geschäftsführer | 28.04.2025 |
| Unternehmen | Position | Ende |
|---|---|---|
| VELOXIS PHARMACEUTICALS A/S | Corporate Officer/Principal | 01.01.2021 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Heron Therapeutics, Inc.
Heron Therapeutics, Inc. BiotechnologyHealth Technology Manufactures and commercializes of polymer technologies | Health Technology |
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients | Health Technology |
University of North Texas
University of North Texas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Calliditas Therapeutics AB
Calliditas Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen